natgillin/translations-raw huggingface dataset:
This selected issue is available in print and on the Internetin English only (http://issues05.emcdda.eu.int).
)Glej tabelo DUP-2 v Statističnem biltenu 2005.)Glej tabelo DUP-4 v Statističnem biltenu 2005.
evaluation of the drugfree zone in one Austrian prisonshowed that prisoners released from the drug-freezonewere sentenced again significantly less oftenthanprisoners released from normal units in the prison(35% compared with 62%).
Alternative zapora, namenjene problematičnimstorilcem kaznivih dejanj, ki uživajo droge v EU, v Letnem poročilu Centra 2005: izbrana vprašanja pobudami, npr. med policijo, sodišči, zapori in službami zazdravljenje odvisnosti od drog.
New developments in combating the spreadofinfectious diseases in prison
Izbrano vprašanje obravnava ukrepe, ki senanašajo na zdravljenje odvisnosti od drog.
The most common treatment modality in prisons is drugfree treatment, which exists in all Member States (except Cyprus and Latvia), although availability varies.
Pogosto se uporabi osrednjisistem zdravljenja, da se zagotovi zdravljenje storilcevsproblematičnim uživanjem drog.
Treatmentcentres within the community provide support andtreatment as well as aftercare in many countries, e.g.Belgium, the Czech Republic, Greece, Luxembourg and the United Kingdom.
V večini državzdravljenje običajno poteka na oddelkih za zdravljenjeodvisnosti, vendar obstaja tudi možnost vključitvevprograme zunajbolnišničnega zdravljenja.
In Estonia, the situation regarding the prevention of thespread of HIV improved in 2003. The number of primary HIV tests increased 2.6-fold compared with 2002,although the number of positive tests increased onlyslightly.
Od leta 1960 naprej so sporazumi, strategije in akcijskinačrti Združenih narodov in EU večkrat potrdili in okrepilinačelo zagotavljanja zdravljenja, izobraževanja inrehabilitacije kot alternativo za obsodbo in kaznovanjekaznivih dejanj, povezanih z drogo.
Pre- and post-test counselling services alsoimproved in terms of quantity as well as quality.
To je bilo prenesenovnacionalne strategije držav članic EU, kazenskipravosodni sistem ter sistemi zdravstvenih in socialnih službpa so se temu primerno prilagodili.
In Romania, programmes aimed at preventing the spread of HIV/AIDS in penitentiaries and among prisoners weredeveloped in cooperation with some international nongovernmental organisations (NGOs).
Mlajše uživalce drogzlasti ogroža možnost, da se bodo zapletli v začarani krogdrog in kriminala, zato obstaja posebna odločenost, da sepri mlajših storilcih izognemo zaporu.
In most countries, the availability of substitutionmaintenance treatment inside prison is not the same as itsavailability outside prison.
Evropske ocenjevalne študije zdravljenja kot alternativezaporu so redke in neverodostojne.
Only in Spain is maintenancetreatment widespread, with 18% of all prisoners, or 82%of problem drug users in prison, receiving this treatment.Luxembourg also has high coverage.
Vendar se v skladuzdrugimi raziskavami zdravljenja zadržanje v zdravljenjuizkaže kot ključni kazalec uspeha, število ljudi, ki prekinezdravljenje, pa je ena od največjih težav za alternativezaporu.
Countries reportingconsiderable increases in the availability of medicallyassisted treatment include France, mainly withbuprenorphine, and Ireland (Reitox national reports).
Dokazi kažejo, da je za uspeh zdravljenjapomembna kakovost zdravljenja in ne način vključitveosebe vanj.
In the Netherlands, medically assisted treatment isavailable only for short-term detainees who used
Zdi se, da zdravljenje kot alternativa zaporunajboljše deluje, če so odvisniki motivirani zanj in čeoskrbovalne ustanove upoštevajo dobre klinične standardeter imajo na voljo zadosti usposobljenega osebja.
EMCDDA (2004a), Annual report 2004: the state of the drugs problem inthe European Union and Norway, European Monitoring Centre on Drugsand Drug Addiction, Lisbon.
EMCDDA (2004a), Letno poročilo 2004: O stanju na področju drog v Evropski uniji in na Norveškem, Evropski center za spremljanje droginzasvojenosti z drogami, Lizbona.
Overdose — a major cause ofavoidable death among young people, European Monitoring Centre on Drugs and Drug Addiction, Lisbon.
Preveliki odmerki – glavni vzroksmrti med mladimi, ki se ji je mogoče izogniti, Evropski center zaspremljanje drog in zasvojenosti z drogami, Lizbona.
Reitox national reports (2004) (http://www.emcdda.eu.int/?nnodeid=435).
Nacionalna poročila Reitox (2004)(http://www.emcdda.eu.int/?nnodeid=435).
WHO (1998), Opioid overdose: trends, risk factors, interventions andpriorities for action, World Health Organisation, Programme on Substance Abuse, Division of Mental Health and Prevention of Substance Abuse,Geneva.
WHO (1998), Opioid overdose: trends, risk factors, interventionsandpriorities for action, Svetovna zdravstvena organizacija, Programozlorabi snovi, Oddelek za duševno zdravje in preprečevanje zlorabesnovi, Ženeva.
Luxembourg: Office for Official Publications of the European Communities2005 — 87 pp. — 21 x 29.7 cm ISBN 92-9168-227-6
Luxembourg: Urad za uradne publikacije Evropskih skupnosti2005 — 89 str. – 21 x 29,7 cm ISBN 92-9168-244-6
THE STATE OF THE DRUGS PROBLEMIN EUROPE
STANJE V ZVEZI S PROBLEMOM DROG V EVROPI
This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright.
Pričujoča publikacija Evropskega centra za spremljanje drog in zasvojenosti z drogami (EMCDDA, v nadaljevanju: Center) je zaščitena z avtorskimi pravicami.
The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document.
Center ne sprejema odgovornosti za posledice, ki izhajajo iz uporabe podatkov iz tega dokumenta.
The contents of this publication do not necessarily reflect the official opinions of the EMCDDA’s partners, the EU Member States or any institution or agency of the European Union or European Communities.
Vsebina te publikacije ne odseva nujno uradnih mnenj partnerjev Centra, držav članic EU ali katere koli ustanove ali agencije Evropske unije ali Evropskih skupnosti.
A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu).
Veliko dodatnih informacij o Evropski uniji je na voljo na internetu.Dostop je mogoč na strežniku Europa (http://europa.eu).
This report is available in Spanish, Czech, Danish, German, Estonian, Greek, English, French, Italian, Latvian, Lithuanian, Hungarian, Dutch, Polish, Portuguese, Slovak, Slovene, Finnish, Swedish, Bulgarian, Romanian, Turkish and Norwegian.
To poročilo je na voljo v španskem, češkem, danskem, nemškem, estonskem, grškem, angleškem, francoskem, italijanskem, latvijskem, litovskem, madžarskem, nizozemskem, poljskem, portugalskem, slovaškem, slovenskem, finskem, švedskem, bolgarskem, romunskem, turškem in norveškem jeziku.
© European Monitoring Centre for Drugs and Drug Addiction, 2006
© Evropski center za spremljanje drog in zasvojenosti z drogami, 2006
Responding to drug problems in Europe — an overview
Odzivi na probleme drog v Evropi – pregled
Opioid use and drug injection
Uživanje opiatov in vbrizgavanje drog
Drugrelated infectious diseases and drugrelated deaths
Z drogo povezane nalezljive bolezni in smrtni primeri
This is the 11th annual report of the European Monitoring Centre for Drugs and Drug Addiction, available this year in 23 European languages.
Pred vami je enajsto letno poročilo Evropskega centra za spremljanje drog in zasvojenosti z drogami, ki je letos na voljo v 23 jezikih.
Looking back across the reports issued by the agency over the years, it is hard not to be struck by the growth in the level of detail in the information now available — reflecting a more complex situation both in the use of illicit drugs in Europe and in the way Europe responds to the drug problem.
Ko primerjamo poročila, ki jih je v preteklih letih izdala agencija, je naravnost osupljivo, kako zelo se je povečala natančnost danes razpoložljivih informacij, in kako te mnogo bolje odražajo zapleteno stanje v Evropi, tako kar se tiče uživanja nedovoljenih drog kot načina, kako se Evropa odziva na problem drog.
and tangible progress has been made. This has meant that European policymakers have had to make difficult choices, and they have largely done so after carefully studying the available evidence.
politike v Evropi imeli zelo težko delo pri sprejemanju odločitev, odločali pa so se večinoma po tem, ko so pazljivo preučili vse razpoložljive podatke.
Such a policy perspective should be applauded.
Takšni usmeritvi politik bi bilo treba zaploskati.
The global debate on the drug problem is not short on rhetoric regarding the need for a balanced and evidence-based approach.
Kadar razprave o problemu drog potekajo na globalni ravni, se vedno mnogo govori o potrebi po uravnoteženem in na dokazih temelječem pristopu.
In Europe, perhaps more than anywhere else, this rhetoric has become reality.
V Evropi so morda bolj kot kjerkoli drugje te besede postale resničnost.
Despite differences between our Member States in the details of the drug problems they each face and in their priorities for action, there is common agreement on the importance of sharing information and cooperating in order to reduce the supply of drugs as well as on the need to balance supply reduction activities with demand reduction measures, and there is a growing consensus regarding the need to be guided by the evidence in making hard choices about what programmes and actions are in the best interests of our citizens.
Kljub razlikam med državami članicami glede posameznih problemov, s katerimi se zaradi drog spopada vsaka med njimi, in kljub razlikam glede prednostnih ukrepov, vse države soglašajo, kako pomembna sta izmenjava informacij in sodelovanje za zmanjšanje dobave drog kot tudi, da je potrebno dejavnosti za zmanjšanje dobave uravnotežiti z ukrepi za zmanjšanje povpraševanja.
The information available to support our analysis has grown considerably.
Količina informacij, ki so na voljo za naše analize, se je močno povečala.
This year’s report is based on data from the 25 EU Member States and Norway and, where available, from Bulgaria, Romania and Turkey.
Letošnje poročilo temelji na podatkih iz 25 držav članic in Norveške ter, kjer so na voljo, tudi na podatkih iz Bolgarije, Romunije in Turčije.
Not only has the number of countries providing information increased, but the amount of comparable information available from each has continued to grow.
Naraslo ni samo število držav, ki posredujejo podatke, ampak je tudi količina primerljivih informacij iz vsake od njih čedalje večja.
This information provides us with a far more detailed picture of the European drug situation and its dynamics than ever before.
S pomočjo teh informacij je slika stanja in trendov v zvezi z drogami v Evropi veliko bolj natančna kot kdajkoli prej.
It is the EMCDDA’s task to explore this complexity, drawing together common experiences where they exist as well as commenting on differences.
Naloga centra EMCDDA je preučiti to zapleteno sliko, strniti podobne izkušnje ter razložiti razlike.
In investing in data collection and collaborating in the work of the centre, our Member States have come to understand that their neighbours’ problems today may become their own problems tomorrow.
Ob zbiranju podatkov in sodelovanju pri delu Centra so države članice spoznale, da lahko težave, ki jih imajo njihovi sosedje danes, postanejo jutri njihovi lastni problemi.
This awareness is evidenced in the new European Union drug strategy and its accompanying action plans, which are underpinned by consensus on the importance of collecting and sharing information; the need to identify and disseminate good practice; and the value of cooperation and coordinated action in response to the common threat to the health, well-being and security of our citizens posed by drugs.
Da se tega zavedajo, je razvidno iz nove strategije EU za boj proti drogam ter spremljevalnih akcijskih načrtov, ki jih dodatno podpira soglasje o nujnosti zbiranja in izmenjave informacij, o potrebi prepoznavanja in razširjanja dobre prakse ter o pomembnosti sodelovanja in usklajevanja dejavnosti kot odziva na skupno grožnjo, ki jo za zdravje, dobrobit in varnost naših državljanov predstavljajo droge.
Drug use is a complex issue, and it is not one that lends itself to simple conclusions.
Uživanje drog je kompleksen pojav in kot tak ne dovoljuje enostavnih zaključkov.
However, one conclusion does clearly emerge from the European experience — we have learned that working together not only works but is also indispensable if we are to develop effective responses to the challenges presented to us by the use of illicit drugs.
Kljub temu pa iz evropske izkušnje jasno izhaja skupna ugotovitev – naučili smo se, da skupno delo ni samo učinkovito, ampak je hkrati tudi nujno potrebno, če se hočemo uspešno odzvati na izzive, s katerimi se spopadamo zaradi nedovoljenih drog.
Marcel Reimen Chairman, EMCDDA Management Board
Marcel Reimen Predsednik upravnega odbora EMCDDA
A reflection on the information available also reminds us of the need for continued vigilance and of the dangers of complacency.
Presoja vseh razpoložljivih informacij nas opozarja tudi, da je potrebna stalna opreznost in da obstaja nevarnost, da bi bili prehitro zadovoljni z rezultati.
Warning notes are sounded in this report in respect of drugrelated HIV infections and drugrelated deaths.
Opozorila v tem poročilu se nanašajo na okužbe s HIV, povezane z uživanjem drog, ter na smrti zaradi drog.
Nonetheless, in Europe as a whole, a tremendous effort has been made to address these sorts of problems,
Evropa kot celota si izjemno prizadeva pri spopadanju s temi problemi in je pri tem že dosegla znaten napredek.
The EMCDDA would like to thank the following for their help in producing this report:
Center se za pomoč pri pripravi tega poročila zahvaljuje: vodjem nacionalnih kontaktnih točk Reitox in njihovemu osebju;
• the heads of the Reitox national focal points and their staff;
• službam v vseh državah članicah, ki so zbirale neobdelane podatke za to poročilo;
• the services within each Member State that collected the raw data for this report;
• članom upravnega odbora in znanstvenega odbora Centra;
• the European Parliament, the Council of the European Union — in particular its Horizontal Working Party on Drugs — and the European Commission;
Evropskemu parlamentu, Svetu Evropske unije – zlasti njegovi horizontalni delovni skupini za droge – in Evropski komisiji;
• the European Centre for Disease Prevention and Control (ECDC) and Europol;
Evropskemu centru za preprečevanje in obvladovanje bolezni (ECDC) in Europolu;
• the Pompidou Group of the Council of Europe, the United Nations Office on Drugs and Crime, the WHO Regional Office for Europe, Interpol, the World Customs Organisation, the Swedish Council for Information on Alcohol and other Drugs (CAN), and the Centre for the Epidemiological Monitoring of AIDS;
Skupini Pompidou Sveta Evrope, Uradu za droge in kriminal pri Združenih narodih, Regionalni pisarni za Evropo pri SZO, Interpolu, Svetovni carinski organizaciji, švedskemu Svetu za informacije o alkoholu in drugih drogah (Council for Information on Alcohol and other Drugs, CAN) in Evropskemu centru za epidemiološko spremljanje aidsa;
• the Translation Centre for Bodies of the European Union and the Office for Official Publications of the European Communities;
Prevajalskemu centru za organe Evropske unije in Uradu za uradne publikacije Evropskih skupnosti;
The network is comprised of national focal points in the EU Member States, Norway, the candidate countries and at the European Commission.
Mrežo sestavljajo nacionalne kontaktne točke v državah članicah EU, na Norveškem, v državah kandidatkah in pri Evropski komisiji.
Under the responsibility of their governments, the focal points are the national authorities providing drug information to the EMCDDA.
Kontaktne točke so pristojni nacionalni organi, za katere so odgovorne njihove vlade in ki informacije o drogah posredujejo centru EMCDDA.
The contact details of the national focal points may be found at:http://www.emcdda.europa.eu/?nnodeid=1596
Kontaktni podatki za posamezne nacionalne kontaktne točke so na razpolago na: http://www.emcdda.europa.eu/?nnodeid=1596
This annual report is based on information provided to the EMCDDA by the EU Member States and candidate countries and Norway (participating in the work of the EMCDDA since 2001) in the form of a national report.
Pričujoče letno poročilo temelji na podatkih, ki so jih v obliki nacionalnih poročil Centru poslale države članice EU, države kandidatke in Norveška (ki sodeluje pri delu Centra od leta 2001).
The statistical data reported here relate to the year 2004 (or the last year available).
Vsi tukaj uporabljeni statistični podatki se nanašajo na leto 2004 (ali na zadnje razpoložljivo leto).
Graphics and tables in this report may reflect a subset of EU countries: the selection is made on the basis of those countries from which data are available for the period of interest.
Grafični prikazi in tabele v tem poročilu lahko odražajo podskupino držav članic EU: izbor je narejen na podlagi tistih držav, katerih podatki so na voljo za zadevno obdobje.
An online version of the annual report is available in 23 languages and may be found at http://annualreport.emcdda.europa.eu
Spletna različica letnega poročila je na voljo v 23 jezikih, in sicer na naslovu http://annualreport.emcdda.europa.eu.
The 2006 statistical bulletin (http://stats06.emcdda.europa.eu) presents the full set of source tables on which the statistical analysis in the annual report is based.
Statistični bilten Centra za leto 2006 (http://stats06.emcdda.europa.eu) vsebuje celoten sklop izvirnih tabel, na katerih temelji statistična analiza v letnem poročilu.
It also provides further details on the methodology used and over 100 additional statistical graphs.
Poleg tega vsebuje dodatne podrobnejše podatke o uporabljeni metodologiji in več kot 100 dodatnih statističnih grafikonov.
Country data profiles (http://dataprofiles06.emcdda.europa.eu) provide a top-level, graphical summary of key aspects of the drug situation for each country.
V profilih posameznih držav (http://dataprofiles06.emcdda.europa.eu) se nahajajo vrhunski grafični povzetki ključnih podatkov o razmerah na področju drog za vsako državo.
Three in-depth reviews accompany this report and explore the following issues:
To poročilo spremljajo tri podrobnejša, krajša poročila, ki obravnavajo naslednja izbrana vprašanja: evropske politike drog: ali segajo prek prepovedanih drog?;
• A gender perspective on drug use and responding to drug problems
• nove okoliščine uživanja drog v sprostitvenih okoljih.
The selected issues are available in print and online (http://issues06.emcdda.europa.eu) in English only.
Izbrana vprašanja so na voljo v tiskani in spletni obliki (http://issues06.emcdda.europa.eu) samo v angleščini.
The national reports of the Reitox focal points give a detailed description and analysis of the drug problem in each country and are available on the EMCDDA website (http://www.emcdda.europa.eu/?nnodeid=435).
Nacionalna poročila kontaktnih točk Reitox navajajo podroben opis in analizo problema drog v vsaki državi in so na voljo na spletni strani centra EMCDDA (http://www.emcdda.europa.eu/?nnodeid=435).
A continuing trend, again evident in the new information reported this year, is for changes to national drug laws to emphasise more strongly a distinction between offences of drug possession for personal use and those involving trafficking and supply.
Nov evropski okvir za usklajevanje in sodelovanje nacionalnih zakonodaj o drogah, ki naj bi bolj poudarile razliko med kaznivimi dejanji zaradi posedovanja drog za osebno uporabo in kaznivimi dejanji, ki vključujejo promet in oskrbo z drogami.
Generally, there is a shift towards increased penalties for the latter and a reduced emphasis on custodial sentences for the former.
Na splošno gre za premik k večjim kaznim za slednja kazniva dejanja in zmanjšanemu poudarku na zaporni kazni za prva.
This development is in line with a greater emphasis overall across Europe on widening the opportunities for drug treatment and on giving more attention to interventions that divert those with drug problems away from the criminal justice system towards treatment and rehabilitation options.
Ta razvoj dogodkov je v skladu z večjim poudarkom, ki ga povsod po Evropi namenjajo večanju možnosti za zdravljenje odvisnosti od drog in intervencijam, ki osebe s težavami zaradi uživanja drog preusmerijo iz kazenskega pravosodnega sistema k možnostim za zdravljenje in rehabilitacijo.
For those countries that have made a legal distinction with respect to the possession of drugs for use rather than supply, the question arises whether there is an explicit need to legislate on what quantities of drugs constitute a threshold for personal use.
V tistih državah, ki so sprejele pravno razlikovanje med posedovanjem droge za lastno uporabo in za prodajo, se pojavlja vprašanje, ali je treba izrecno z zakonom določiti, katera količina droge pomeni zgornjo mejo za osebno uporabo.
Here no consensus currently prevails and different approaches have been adopted across Europe, ranging from the issuing of general operational guidelines through to specification of legal limits.
Glede tega trenutno ni prevladujočega soglasja, evropske države pa so sprejele različne pristope, ki segajo od izdaje splošnih operativnih smernic do določitve pravnih omejitev.
Heroin use: an important part of a bigger picture
Uživanje heroina: pomemben del veliko večje slike
Although defining national drug policies remains the prerogative of individual European Member States, there is now strong agreement on the benefits that can accrue from working together at the European level.
Čeprav ostaja določitev nacionalnih politik o drogah posebna pravica posameznih evropskih držav članic, obstaja sedaj trdno soglasje glede tega, kakšne so lahko prednosti, ki izhajajo iz sodelovanja na evropski ravni.
This can be seen in a number of recent developments that support coordination and cooperation activities.
To je razvidno iz mnogih nedavnih dogodkov, ki podpirajo dejavnosti usklajevanja in sodelovanja.
Among these developments are the coming into force in 2005 of two new EC regulations on precursors and a Council decision on new drugs.
Sem se prišteva začetek veljavnosti dveh novih uredb ES o predhodnih sestavinah in sklepa Sveta o novih drogah, ki so stopili v veljavo leta 2005.
In addition, measures against drug trafficking are strengthened by new legal instruments to address money laundering and confiscation of assets.
Tudi ukrepi za boj proti prometu s prepovedanimi drogami so okrepljeni z novimi pravnimi instrumenti za preprečevanje pranja denarja in za zaplembo premoženja.
However, the development that is most central to shaping European collaboration and future actions on the drug issue is the new EU drug strategy for 2005–12 and its two accompanying action plans.
Vendar pa je najpomembnejši dogodek v zvezi z oblikovanjem evropskega sodelovanja in prihodnjih ukrepov v zvezi z vprašanjem drog, nova strategija EU na področju drog za obdobje 2005–2012 in njena dva spremljevalna akcijska načrta.
In the first of these, around 100 planned specific actions are detailed by EU Member States to be implemented by 2008.
V prvem so države članice EU podrobno določile približno 100 predvidenih posebnih ukrepov, ki naj bi se začeli izvajati do leta 2008.
A continuous programme of evaluation is envisaged for the strategy, with annual progress reviews and impact assessments at the end of each of the two action plan periods.
Za strategijo je predviden stalen program vrednotenja, skupaj z letnimi poročili o napredku in presojami vpliva na koncu vsakega dvoletnega obdobja iz obeh akcijskih načrtov.